Incyte Announces Positive Phase 3 Results for Vitiligo cream
Primary and key secondary endpoints met in both TRuE-V1 and TRuE-V2 studies Data will support planned ...
Read morePrimary and key secondary endpoints met in both TRuE-V1 and TRuE-V2 studies Data will support planned ...
Read moreEli Lilly and Company and Incyte announced that the U.S. Food and Drug Administration (FDA) has ...
Read moreIncyte today announced that the European Commission (EC) has approved Pemazyre® (pemigatinib) for the treatment of adults ...
Read moreIncyte today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Pemazyre® ...
Read moreAddress: | Pharma Reg News, First floor, Shop no.1 , Plot no 241,242, Near Fire station, GIDC, Ankleshwar, Gujarat - 393002. |
Phone: | +91 8511586232, +91 9029066605 |
Email: | author@pharmaregnews.com |
© 2021 - Pharmaregnews.com. Developed by YESWEUS.
© 2021 - Pharmaregnews.com. Developed by YESWEUS.